Phase 1 safety and efficacy of IMC-F106C, a PRAME x CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM) Meeting Abstract
| Authors: | Hamid, O.; Williams, A.; Lopez, J. S.; Olson, D.; Sato, T.; Shaw, H. M.; Friedman, C. F.; Thistlethwaite, F.; Middleton, M. R.; Lebbe, C.; Ma, V. T.; Izar, B.; Lau, P. K. H.; Bechter, O. E.; Kirk, P.; Yuan, Y.; Marshall, S.; Davar, D. |
| Abstract Title: | Phase 1 safety and efficacy of IMC-F106C, a PRAME x CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557402201 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.9507 |
| Notes: | Meeting Abstract: 9507 -- Source: Wos |
